Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.590 PosttranslationalModification disease BEFREE RESULTS The incidence of FHIT and p16 methylation in serum from the liver cancer group was 51.8% and 67.9%, respectively. 30773529 2019
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.590 AlteredExpression disease BEFREE The p16 protein expressions in liver cancer and para-carcinoma tissues were detected via immunohistochemistry (IHC), and the correlations of p16 positive expression with ultrasound parameters were also analyzed. 30509095 2019
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.590 Biomarker disease BEFREE These results are significant because they suggest that nucleolar p14ARF can be used as early prognostic marker in chronic liver disease to reliably identify patients with high risk for developing liver cancer. 29228217 2018
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.590 Biomarker disease CTD_human Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. 27064257 2016
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.590 Biomarker disease BEFREE Yet Bmi1 functions independent of Ink4A/Arf repression in liver cancer development. 19934271 2009
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.590 AlteredExpression disease BEFREE Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer. 16317707 2005
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.590 Biomarker disease CTD_human Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer. 16317707 2005
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.590 Biomarker disease RGD Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer. 16317707 2005
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.590 Biomarker disease CTD_human Abnormalities of the ARF-p53 pathway in primary angiosarcomas of the liver. 12378512 2002
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.590 Biomarker disease RGD De novo methylation of the p16INK4A gene in early preneoplastic liver and tumors induced by folate/methyl deficiency in rats. 12359353 2002
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.590 Biomarker disease RGD Sequential changes in hepatocarcinogenesis induced by diethylnitrosamine plus thioacetamide in Fischer 344 rats: induction of gankyrin expression in liver fibrosis, pRB degradation in cirrhosis, and methylation of p16(INK4A) exon 1 in hepatocellular carcinoma. 11301474 2001
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.590 GeneticVariation disease BEFREE The purpose of the current investigation was to define the prevalence of genetic alterations in p16 and beta-catenin in NNK-induced rat liver cancer to determine if the molecular mechanisms seen in human tumors are the same in this animal model. 11238187 2001
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.590 PosttranslationalModification disease BEFREE Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. 9892188 1999
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.590 Biomarker disease BEFREE Alterations of CDKN2 (MTS1/p16INK4A) gene in paraffin-embedded tumor tissues of human stomach, lung, cervix and liver cancers. 9873831 1998
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.590 PosttranslationalModification disease BEFREE Infrequent alterations of the p16INK4A gene in liver cancer. 8760583 1996